Karo Pharma AB (OSTO:KARO BTA) EV-to-EBIT : 1.72 (As of Jun. 08, 2024)

Karo Pharma AB EV-to-EBIT Chart

Karo Pharma AB Annual Data
	Trend	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21
EV-to-EBIT		Get a 7-Day Free Trial					71.22	19.75	76.93	68.67	97.10

Karo Pharma AB Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Jun22
EV-to-EBIT	Get a 7-Day Free Trial															61.40	89.02	69.67	97.10	610.08

Competitive Comparison of Karo Pharma AB's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Karo Pharma AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Karo Pharma AB's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Karo Pharma AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Karo Pharma AB's EV-to-EBIT falls into.

Karo Pharma AB EV-to-EBIT Calculation

Karo Pharma AB's EV-to-EBIT for today is calculated as:

Karo Pharma AB's current Enterprise Value is kr336 Mil.
Karo Pharma AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was kr196 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karo Pharma AB  (OSTO:KARO BTA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Karo Pharma AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2022 is calculated as:

Karo Pharma AB's Enterprise Value for the quarter that ended in Jun. 2022 was kr0 Mil.
Karo Pharma AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was kr196 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karo Pharma AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Karo Pharma AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Karo Pharma AB (OSTO:KARO BTA) Business Description